Qi Biodesign Completes $75 Million in Total Funding to Drive Genome Editing Innovations

December 06, 2024 11:15 PM AEDT | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

BEIJING, Dec. 6, 2024 /PRNewswire/ -- Qi Biodesign, a biotechnology company pioneering next-generation genome editing technologies, announced the completion of its Series A funding round. The company has now raised a total of $75 million across its Seed, Series Pre-A, and Series A stages. The Series A round was led by the Beijing Medical and Health Care Industry Investment Fund (Limited Partnership), with additional investments from Beijing Changping Technology Innodevelop Group, Mingzhe Capital, and returning investor CD Capital. Previous investors also include Apricot Capital, Source Code Capital, Gaorong Ventures, CSSD Capital, Shang Capital, and CASSTAR.

Qi Biodesign was founded in 2021 by leading genome editing scientists Dr. Caixia Gao and Dr. Kevin Zhao (Chief Technology Officer), and industry experts Dr. Bei Zhang (Chief Executive Officer), and Haiquan Yang (Chief Business Officer). Qi Biodesign has established itself as a leader in genomic innovation with its proprietary SEEDIT™ research platform, featuring advanced genome editing tools such as novel RNA-guided nucleases, base editors, plant prime editors, and PrimeRoot™ editors for precise large DNA insertions and manipulations. These technologies enable multiplex gene editing, fine-tuning of gene expression, and high-throughput trait discovery, driving the development of superior biological traits to address global challenges in crop breeding and synthetic biology.

Qi Biodesign has already achieved significant milestones in product development, including receiving two biosafety certificates for gene-edited plants (high oleic acid soybean and powdery mildew disease-resistant wheat) by the China Ministry of Agriculture and Rural Affairs and securing an exemption for a gene-edited product (high oleic acid soybean) from the US Department of Agriculture. More gene-edited traits including yield enhancements, herbicide tolerance and quality improvements are advancing through regulatory pipelines. Qi Biodesign's plant breeding innovations advance the application of gene editing in agriculture, contributing to food security and sustainable developments.

The newly secured funding will be used to enhance Qi Biodesign's R&D capabilities, advance its proprietary SEEDIT™ platform, support its product development and build commercialization platforms to streamline and speed up the transition from research to market.

For more information, visit  http://www.qi-biodesign.com

CONTACT: Yihui Jiang, [email protected] 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

Two ASX Listed Stocks Giving Bullish Indications

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.